Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Mol Autism ; 12(1): 16, 2021 02 24.
Article in English | MEDLINE | ID: mdl-33627187

ABSTRACT

BACKGROUND: CHD8 haploinsufficiency causes autism and macrocephaly with high penetrance in the human population. Chd8 heterozygous mice exhibit relatively subtle brain overgrowth and little gene expression changes in the embryonic neocortex. The purpose of this study was to generate new, sub-haploinsufficient Chd8 mouse models to allow us to identify and study the functions of CHD8 during embryonic cortical development. METHODS: To examine the possibility that certain phenotypes may only appear at sub-heterozygous Chd8 levels in the mouse, we created an allelic series of Chd8-deficient mice to reduce CHD8 protein levels to approximately 35% (mild hypomorph), 10% (severe hypomorph) and 0% (neural-specific conditional knockout) of wildtype levels. We used RNA sequencing to compare transcriptional dysregulation, structural MRI and brain weight to investigate effects on brain size, and cell proliferation, differentiation and apoptosis markers in immunostaining assays to quantify changes in neural progenitor fate. RESULTS: Mild Chd8 hypomorphs displayed significant postnatal lethality, with surviving animals exhibiting more pronounced brain hyperplasia than heterozygotes. Over 2000 genes were dysregulated in mild hypomorphs, including autism-associated neurodevelopmental and cell cycle genes. We identify increased proliferation of non-ventricular zone TBR2+ intermediate progenitors as one potential cause of brain hyperplasia in these mutants. Severe Chd8 hypomorphs displayed even greater transcriptional dysregulation, including evidence for p53 pathway upregulation. In contrast to mild hypomorphs, these mice displayed reduced brain size and increased apoptosis in the embryonic neocortex. Homozygous, conditional deletion of Chd8 in early neuronal progenitors resulted in pronounced brain hypoplasia, partly caused by p53 target gene derepression and apoptosis in the embryonic neocortex. Limitations Our findings identify an important role for the autism-associated factor CHD8 in controlling the proliferation of intermediate progenitors in the mouse neocortex. We propose that CHD8 has a similar function in human brain development, but studies on human cells are required to confirm this. Because many of our mouse mutants with reduced CHD8 function die shortly after birth, it is not possible to fully determine to what extent reduced CHD8 function results in autism-associated behaviours in mice. CONCLUSIONS: Together, these findings identify important, dosage-sensitive functions for CHD8 in p53 pathway repression, neurodevelopmental gene expression and neural progenitor fate in the embryonic neocortex. We conclude that brain development is acutely sensitive to reduced CHD8 expression and that the varying sensitivities of different progenitor populations and cellular processes to CHD8 dosage result in non-linear effects on gene transcription and brain growth. Shaun Hurley, Conor Mohan and Philipp Suetterlin have contributed equally to this work.


Subject(s)
Autistic Disorder/genetics , Brain/growth & development , DNA-Binding Proteins/genetics , Animals , Animals, Newborn , Behavior, Animal , Brain/diagnostic imaging , Brain/embryology , Cell Proliferation , DNA-Binding Proteins/deficiency , Disease Models, Animal , Female , Gene Expression Regulation, Developmental , Mice, Transgenic , Phenotype , Pregnancy , Stem Cells , Tumor Suppressor Protein p53/genetics
2.
Cereb Cortex ; 28(6): 2192-2206, 2018 06 01.
Article in English | MEDLINE | ID: mdl-29668850

ABSTRACT

Truncating CHD8 mutations are amongst the highest confidence risk factors for autism spectrum disorder (ASD) identified to date. Here, we report that Chd8 heterozygous mice display increased brain size, motor delay, hypertelorism, pronounced hypoactivity, and anomalous responses to social stimuli. Whereas gene expression in the neocortex is only mildly affected at midgestation, over 600 genes are differentially expressed in the early postnatal neocortex. Genes involved in cell adhesion and axon guidance are particularly prominent amongst the downregulated transcripts. Resting-state functional MRI identified increased synchronized activity in cortico-hippocampal and auditory-parietal networks in Chd8 heterozygous mutant mice, implicating altered connectivity as a potential mechanism underlying the behavioral phenotypes. Together, these data suggest that altered brain growth and diminished expression of important neurodevelopmental genes that regulate long-range brain wiring are followed by distinctive anomalies in functional brain connectivity in Chd8+/- mice. Human imaging studies have reported altered functional connectivity in ASD patients, with long-range under-connectivity seemingly more frequent. Our data suggest that CHD8 haploinsufficiency represents a specific subtype of ASD where neuropsychiatric symptoms are underpinned by long-range over-connectivity.


Subject(s)
Brain/physiopathology , DNA-Binding Proteins/genetics , Gene Expression Regulation, Developmental/genetics , Neural Pathways/physiopathology , Animals , Autism Spectrum Disorder/genetics , Disease Models, Animal , Haploinsufficiency , Mice , Mice, Knockout , Neocortex/metabolism , Transcriptome
3.
Cell Rep ; 21(10): 2772-2784, 2017 Dec 05.
Article in English | MEDLINE | ID: mdl-29212025

ABSTRACT

We describe molecular convergence between BMI1 and CHD7 in the initiation of medulloblastoma. Identified in a functional genomic screen in mouse models, a BMI1High;CHD7Low expression signature within medulloblastoma characterizes patients with poor overall survival. We show that BMI1-mediated repression of the ERK1/2 pathway leads to increased proliferation and tumor burden in primary human MB cells and in a xenograft model, respectively. We provide evidence that repression of the ERK inhibitor DUSP4 by BMI1 is dependent on a more accessible chromatin configuration in G4 MB cells with low CHD7 expression. These findings extend current knowledge of the role of BMI1 and CHD7 in medulloblastoma pathogenesis, and they raise the possibility that pharmacological targeting of BMI1 or ERK may be particularly indicated in a subgroup of MB with low expression levels of CHD7.


Subject(s)
DNA-Binding Proteins/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Medulloblastoma/metabolism , Polycomb Repressive Complex 1/metabolism , Proto-Oncogene Proteins/metabolism , Animals , Blotting, Western , Cell Proliferation/genetics , Cell Proliferation/physiology , Chromatin/genetics , Chromatin/metabolism , DNA-Binding Proteins/genetics , Extracellular Signal-Regulated MAP Kinases/genetics , Female , Male , Medulloblastoma/genetics , Mice , Polycomb Repressive Complex 1/genetics , Protein Tyrosine Phosphatases/genetics , Protein Tyrosine Phosphatases/metabolism , Proto-Oncogene Proteins/genetics , Signal Transduction/genetics , Signal Transduction/physiology
4.
Neuron ; 84(4): 740-52, 2014 Nov 19.
Article in English | MEDLINE | ID: mdl-25451192

ABSTRACT

EphrinAs and EphAs play critical roles during topographic map formation in the retinocollicular projection; however, their complex expression patterns in both the retina and superior colliculus (SC) have made it difficult to uncover their precise mechanisms of action. We demonstrate here that growth cones of temporal axons collapse when contacting nasal axons in vitro, and removing ephrinAs from axonal membranes by PI-PLC treatment abolishes this response. In conditional knockout mice, temporal axons display no major targeting defects when ephrinA5 is removed only from the SC, but substantial mapping defects were observed when ephrinA5 expression was removed from both the SC and from the retina, with temporal axons invading the target areas of nasal axons. Together, these data indicate that ephrinA5 drives repellent interactions between temporal and nasal axons within the SC, and demonstrates for the first time that target-independent mechanisms play an essential role in retinocollicular map formation in vivo.


Subject(s)
Axons/physiology , Ephrins/metabolism , Receptors, Eph Family/metabolism , Retina/physiology , Superior Colliculi/physiology , Animals , Growth Cones/physiology , Mice , Visual Pathways/physiology
5.
J Neurosci ; 34(3): 969-79, 2014 Jan 15.
Article in English | MEDLINE | ID: mdl-24431455

ABSTRACT

A crucial step in the development of the vertebrate visual system is the branching of retinal ganglion cell (RGC) axons within their target, the superior colliculus/tectum. A major player in this process is the neurotrophin brain-derived neurotrophic factor (BDNF). However, the molecular basis for the signaling pathways mediating BDNF action is less well understood. As BDNF exerts some of its functions by controlling the expression of microRNAs (miRNAs), we investigated whether miRNAs are also involved in BDNF-mediated retinal axon branching. Here, we demonstrate that the expression pattern of miRNA-132 in the retina is consistent with its involvement in this process, and that BDNF induces the upregulation of miRNA-132 in retinal cultures. Furthermore, in vitro gain-of-function and loss-of-function approaches in retinal cultures reveal that miRNA-132 mediates axon branching downstream of BDNF. A known target of miRNA-132 is the Rho family GTPase-activating protein, p250GAP. We find that p250GAP is expressed in RGC axons and mediates the effects of miRNA-132 in BDNF-induced branching. BDNF treatment or overexpression of miRNA-132 leads to a reduction in p250GAP protein levels in retinal cultures, whereas the overexpression of p250GAP abolishes BDNF-induced branching. Finally, we used a loss-of-function approach to show that miRNA-132 affects the maturation of RGC termination zones in the mouse superior colliculus in vivo, while their topographic targeting remains intact. Together, our data indicate that BDNF promotes RGC axon branching during retinocollicular/tectal map formation via upregulation of miRNA-132, which in turn downregulates p250GAP.


Subject(s)
Axons/metabolism , Brain-Derived Neurotrophic Factor/pharmacology , GTPase-Activating Proteins/physiology , MicroRNAs/physiology , Retinal Ganglion Cells/metabolism , Animals , Axons/drug effects , Cells, Cultured , Chick Embryo , Female , GTPase-Activating Proteins/deficiency , Mice , Mice, Inbred C57BL , Pregnancy , Retinal Ganglion Cells/drug effects
6.
J Neurosci ; 33(12): 5399-410, 2013 Mar 20.
Article in English | MEDLINE | ID: mdl-23516305

ABSTRACT

Axonal branches of the trigeminal ganglion (TG) display characteristic growth and arborization patterns during development. Subsets of TG neurons express different receptors for growth factors, but these are unlikely to explain the unique patterns of axonal arborizations. Intrinsic modulators may restrict or enhance cellular responses to specific ligands and thereby contribute to the development of axon growth patterns. Protein tyrosine phosphatase receptor type O (PTPRO), which is required for Eph receptor-dependent retinotectal development in chick and for development of subsets of trunk sensory neurons in mouse, may be such an intrinsic modulator of TG neuron development. PTPRO is expressed mainly in TrkB-expressing (TrkB(+)) and Ret(+) mechanoreceptors within the TG during embryogenesis. In PTPRO mutant mice, subsets of TG neurons grow longer and more elaborate axonal branches. Cultured PTPRO(-/-) TG neurons display enhanced axonal outgrowth and branching in response to BDNF and GDNF compared with control neurons, indicating that PTPRO negatively controls the activity of BDNF/TrkB and GDNF/Ret signaling. Mouse PTPRO fails to regulate Eph signaling in retinocollicular development and in hindlimb motor axon guidance, suggesting that chick and mouse PTPRO have different substrate specificities. PTPRO has evolved to fine tune growth factor signaling in a cell-type-specific manner and to thereby increase the diversity of signaling output of a limited number of receptor tyrosine kinases to control the branch morphology of developing sensory neurons. The regulation of Eph receptor-mediated developmental processes by protein tyrosine phosphatases has diverged between chick and mouse.


Subject(s)
Axons/physiology , Membrane Glycoproteins/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-ret/metabolism , Receptor-Like Protein Tyrosine Phosphatases, Class 3/metabolism , Trigeminal Ganglion/cytology , Trigeminal Ganglion/metabolism , Animals , Animals, Newborn , Cells, Cultured , Female , Green Fluorescent Proteins/genetics , HEK293 Cells , HeLa Cells , Humans , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Transgenic , Motor Neurons/cytology , Motor Neurons/metabolism , Pregnancy , Receptor, EphA1/metabolism , Receptor, trkA/metabolism , Receptor, trkC/metabolism , Signal Transduction/physiology , Trigeminal Ganglion/embryology , Trigeminal Nerve/cytology , Trigeminal Nerve/embryology , Trigeminal Nerve/metabolism
7.
Semin Cell Dev Biol ; 23(1): 1-6, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22040913

ABSTRACT

In the classical view of axon guidance, neurons send out axons which are endowed with guidance receptors enabling them to find their (distant) target areas by an interaction with their ligands expressed in specific spatio-temporal patterns along their pathways and in their target area. However, this view has recently been confounded by more detailed analyses of, for example, the expression patterns of EphAs and ephrinAs in the retinotectal projection. Here ephrinA 'ligands' are expressed not only in the target area but also on the projecting RGC axons, and EphA 'receptors' not only on retinal ganglion cell (RGC) axons but also in the target area itself. This review describes the on-going functional characterisation of the surprising co-expression of ephrinAs and EphAs on retinal ganglion cell (RGC) axons and other cell types. It also investigates the function of ephrinAs as receptors and describes their interaction with co-receptors involved in mediating this function.


Subject(s)
Axons/metabolism , Brain/anatomy & histology , Ephrins/physiology , Receptors, Eph Family/metabolism , Animals , Brain/cytology , Brain Mapping , Ephrins/genetics , Ephrins/metabolism , Gene Expression , Humans , Motor Neurons/metabolism , Receptors, Eph Family/genetics , Receptors, Nerve Growth Factor/metabolism , Signal Transduction , Visual Perception
8.
J Neurosci Res ; 88(4): 735-45, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19798744

ABSTRACT

The diacylglycerol lipases (DAGLalpha and DAGLbeta) synthesize 2-arachidonoylglycerol (2-AG), a full agonist at cannabinoid receptors. Dynamic regulation of DAGL expression underpins its role in axonal growth and guidance during development, retrograde synaptic signalling at mature synapses, and maintenance of adult neurogenesis. We show here that DAGLalpha expression is dramatically down-regulated when neural stem (NS) cells are differentiated toward a gamma-aminobutyric acidergic neuronal phenotype. To understand how DAGLalpha expression might be controlled, we sought to identify the core promoter region and regulatory elements within it. The core promoter was identified and shown to contain both an enhancer and a suppressor region. Deletion analysis identified two elements, including a GC-box, that specifically promote expression in NS cells. Bioinformatic analysis identified three candidate transcription factors that might regulate DAGLalpha expression in NS cells by binding to the GC box; these were specificity protein 1 (Sp1), early growth response element 1 (EGR1), and zinc finger DNA-binding protein 89 (ZBP-89). However, Sp1 was the only factor that could bind to the GC-box. A specific mutation within the GC-box that inhibited Sp1 binding reduced DAGLalpha promoter activity in NS cells. Likewise, a dominant negative Sp1 was shown to bind to the GC-box and to suppress DAGLalpha promoter activity specifically in NS cells. Finally, like DAGLalpha, Sp1 was down-regulated during neuronal differentiation. A full characterization of the DAGLalpha promoter will help to elucidate the upstream pathways that regulate DAGLalpha expression in NS cells and their progeny.


Subject(s)
Cell Differentiation/physiology , Down-Regulation/physiology , Embryonic Stem Cells/physiology , Lipoprotein Lipase/metabolism , Transcription Factors/physiology , Animals , Cell Line, Transformed , Cerebral Cortex/cytology , Chlorocebus aethiops , Down-Regulation/drug effects , Electrophoretic Mobility Shift Assay/methods , Embryonic Stem Cells/drug effects , Epidermal Growth Factor/pharmacology , Fibroblast Growth Factor 2/pharmacology , Glial Fibrillary Acidic Protein/metabolism , Humans , Lipoprotein Lipase/genetics , Mice , Mutagenesis/genetics , Protein Binding , Time Factors , Transfection/methods , Tubulin/metabolism
9.
Mol Cell Neurosci ; 38(4): 526-36, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18562209

ABSTRACT

The subventricular zone (SVZ) is a major site of neurogenesis in the adult. We now show that ependymal and proliferating cells in the adult mouse SVZ express diacylglycerol lipases (DAGLs), enzymes that synthesise a CB1/CB2 cannabinoid receptor ligand. DAGL and CB2 antagonists inhibit the proliferation of cultured neural stem cells, and the proliferation of progenitor cells in young animals. Furthermore, CB2 agonists stimulate progenitor cell proliferation in vivo, with this effect being more pronounced in older animals. A similar response was seen with a fatty acid amide hydrolase (FAAH) inhibitor that limits degradation of endocannabinoids. The effects on proliferation were mirrored in changes in the number of neuroblasts migrating from the SVZ to the olfactory bulb (OB). In this context, CB2 antagonists reduced the number of newborn neurons appearing in the OB in the young adult animals while CB2 agonists stimulated this in older animals. These data identify CB2 receptor agonists and FAAH inhibitors as agents that can counteract the naturally observed decline in adult neurogenesis that is associated with ageing.


Subject(s)
Aging/physiology , Cell Differentiation/physiology , Cerebral Ventricles/growth & development , Lipoprotein Lipase/physiology , Receptor, Cannabinoid, CB2/physiology , Signal Transduction/physiology , Age Factors , Animals , Cell Line , Cells, Cultured , Cerebral Ventricles/cytology , Cerebral Ventricles/enzymology , Female , Mice , Mice, Inbred C57BL , Mice, Knockout , Neurons/cytology , Neurons/enzymology , Neurons/physiology , Stem Cells/cytology , Stem Cells/enzymology , Stem Cells/physiology
10.
Mol Cell Neurosci ; 38(3): 374-80, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18499473

ABSTRACT

Evidence is emerging that the tumour necrosis factor (TNF-alpha) is a potent signal that induces neural stem cell proliferation and migration. We show that NSC self-renewal is controlled by bi-directional cross-talk between the endocannabinoid system and the TNF signalling pathway. By blocking endogenous TNF-alpha activity, we demonstrate that the TNF system is critical for the proliferation of NSC. Furthermore, we show that pharmacological blockade of the CB1/CB2 cannabinoid receptors dramatically suppresses TNF-alpha-induced NSC proliferation. Interestingly, we found that CB1 or CB2 agonists induce NSC proliferation coupled to a significant increase in both TACE/ADAM 17 and TNF-alpha levels. Overall these data suggest a novel mode of action for the endocannabinoid system in NSC proliferation that is coupled to TNF signalling and that may be of therapeutic interest in the emerging field of brain repair.


Subject(s)
Cannabinoid Receptor Modulators/physiology , Cell Proliferation , Endocannabinoids , Neurons/physiology , Signal Transduction/physiology , Stem Cells/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Cannabinoid Receptor Agonists , Cannabinoid Receptor Antagonists , Cell Differentiation/physiology , Cells, Cultured , Mice , Neurons/cytology , Receptors, Cannabinoid/physiology , Stem Cells/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...